ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS

BACKGROUND: Clinical benefit of continuing bevacizumab beyond progression is unknown in glioblastomas. A biomarker analysis of the AVAglio trial suggested that proneural subtype of IDH-wildtype glioblastoma patients may receive an OS benefit from a first-line bevacizumab. This study explored biomark...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Ichimura, Koichi, Nagane, Motoo, Kato, Mamoru, Narita, Yoshitaka, Aoki, Tomokazu, Tanaka, Shota, Mukasa, Akitake, Wakabayashi, Toshihiko, Uzuka, Takeo, Nakamura, Hideo, Arakawa, Yoshiki, Suehiro, Satoshi, Nakada, Mitsutoshi, Kitahara, Mai, Hibiya, Yuko, Narushima, Daichi, Onuki, Ritsuko, Morita, Satoshi, Nishikawa, Ryo
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2019
נושאים:
Adult Clinical Trials - Non-Immunologic
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846955/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.048
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים